Skip to main content
. 2020 Sep 9;12(9):858. doi: 10.3390/pharmaceutics12090858

Table 6.

In vivo efficacy studies in a Leishmania infantum visceral murine model. Parasite burden in liver, spleen and BM was measured by qRT-PCR after 5 or 10 consecutive days of i.p. treatment with free BER and LP-BER at 5, 10 and 15 mg/kg. Fungizone® (FGZ) i.v. administered at 1 mg/kg was used as positive control. Results expressed as median ± 95% IC (n = 6 per group). Data analyzed using a nonparametric Kruskal–Wallis test, followed by Dunn’s multiple comparison. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.

Liver Spleen BM (Bone Marrow)
Dose (mg/kg) Median 95% IC Median 95% IC Median 95% IC
5 Days Control 3.4 × 107 4 × 106–8 × 107 2.8 × 103 1 × 103–5 × 103 5.6 × 105 3 × 105–1 × 106
5 BER 4.4 × 106 9 × 105–1 × 107 2.5 × 103 6 × 102–2 × 104 8.7 × 105 2 × 105–3 × 106
LP-BER 3.5 × 107 1 × 107–1 × 108 2.9 × 103 2 × 103–1 × 104 1.1 × 106 2 × 105–4 × 106
10 BER 4.9 × 107 2 × 107–1 × 108 2.3 × 103 7 × 102–9 × 103 2.0 × 106 8 × 105–3 × 106
LP-BER 1.7 × 107 7 × 106–5 × 107 2.5 × 103 2 × 103–6 × 103 6.6 × 105 1 × 105–1 × 106
1 FGZ 8.0 × 105 3 × 105–1 × 107 6.0 × 102 2 × 102–2 × 103 2.3 × 105 2 × 104–5 × 105
10 Days Control 5.0 × 107 4 × 105–9 × 107 6.1 × 103 2 × 103–1 × 104 5.1 × 105 8 × 104–2 × 106
15 BER 7.3 × 106 1 × 106–2 × 107 1.1 × 103 4 × 102–3 × 104 7.9 × 105 1 × 105–3 × 106
LP-BER 5.6 × 104 * 1 × 104–2 × 106 3.2 × 102 ** 2 × 102–9 × 102 1.1 × 106 8 × 104–5 × 106
1 FGZ 1.8 × 102 *** 1–7 × 102 5.2 **** 1–1 × 101 1.3 × 101 * 6–2 × 101